Trial Profile
A Single Center, Retrospective, Observational Study Assessing the Efficacy and Safety of Subcutaneous Ustekinumab in Paediatric Patients with Severe, Refractory Crohn's Disease (CD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2017
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2017 New trial record
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week.